Literature DB >> 19860647

Gene therapy continues to make progress: clinical and regulatory perspectives.

Maria G Castro, Pedro R Lowenstein.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19860647      PMCID： PMC4652322          DOI： 10.2174/156652309789753374

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN： 1566-5232            Impact factor:   4.391


× No keyword cloud information.
  13 in total

1.  A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.

Authors:  Salima Hacein-Bey-Abina; Christof von Kalle; Manfred Schmidt; Françoise Le Deist; Nicolas Wulffraat; Elisabeth McIntyre; Isabelle Radford; Jean-Luc Villeval; Christopher C Fraser; Marina Cavazzana-Calvo; Alain Fischer
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

Review 2.  Gene therapy of inherited diseases.

Authors:  Alain Fischer; Marina Cavazzana-Calvo
Journal:  Lancet       Date:  2008-06-14       Impact factor: 79.321

3.  Drugs and adverse drug reactions: how worried should we be?

Authors:  D W Bates
Journal:  JAMA       Date:  1998-04-15       Impact factor: 56.272

4.  Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.

Authors:  J Lazarou; B H Pomeranz; P N Corey
Journal:  JAMA       Date:  1998-04-15       Impact factor: 56.272

5.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.

Authors:  M Cavazzana-Calvo; S Hacein-Bey; G de Saint Basile; F Gross; E Yvon; P Nusbaum; F Selz; C Hue; S Certain; J L Casanova; P Bousso; F L Deist; A Fischer
Journal:  Science       Date:  2000-04-28       Impact factor: 47.728

6.  Gene therapy for immunodeficiency due to adenosine deaminase deficiency.

Authors:  Alessandro Aiuti; Federica Cattaneo; Stefania Galimberti; Ulrike Benninghoff; Barbara Cassani; Luciano Callegaro; Samantha Scaramuzza; Grazia Andolfi; Massimiliano Mirolo; Immacolata Brigida; Antonella Tabucchi; Filippo Carlucci; Martha Eibl; Memet Aker; Shimon Slavin; Hamoud Al-Mousa; Abdulaziz Al Ghonaium; Alina Ferster; Andrea Duppenthaler; Luigi Notarangelo; Uwe Wintergerst; Rebecca H Buckley; Marco Bregni; Sarah Marktel; Maria Grazia Valsecchi; Paolo Rossi; Fabio Ciceri; Roberto Miniero; Claudio Bordignon; Maria-Grazia Roncarolo
Journal:  N Engl J Med       Date:  2009-01-29       Impact factor: 91.245

Review 7.  Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy.

Authors:  M S Hershfield
Journal:  Semin Hematol       Date:  1998-10       Impact factor: 3.851

8.  Gene therapy improves immune function in preadolescents with X-linked severe combined immunodeficiency.

Authors:  Javier Chinen; Joie Davis; Suk See De Ravin; Beverly N Hay; Amy P Hsu; Gilda F Linton; Nora Naumann; Effie Y H Nomicos; Christopher Silvin; Jean Ulrick; Narda L Whiting-Theobald; Harry L Malech; Jennifer M Puck
Journal:  Blood       Date:  2007-03-16       Impact factor: 22.113

9.  Investigation of the cause of death in a gene-therapy trial.

Authors:  Karen M Frank; D Kyle Hogarth; Jonathan L Miller; Saptarshi Mandal; Philip J Mease; R Jude Samulski; Glen A Weisgerber; John Hart
Journal:  N Engl J Med       Date:  2009-07-09       Impact factor: 91.245

10.  Arthritis gene therapy's first death.

Authors:  Christopher H Evans; Steven C Ghivizzani; Paul D Robbins
Journal:  Arthritis Res Ther       Date:  2008-05-27       Impact factor: 5.156
View more
  2 in total

Review 1.  The value of EGFRvIII as the target for glioma vaccines.

Authors:  Pedro R Lowenstein; Maria G Castro
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

Review 2.  Gene therapy from the perspective of systems biology.

Authors:  Feilim Mac Gabhann; Brian H Annex; Aleksander S Popel
Journal:  Curr Opin Mol Ther       Date:  2010-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.